|
|
Vaccine Detail
|
Autologous Neuroblastoma Vaccine |
| Vaccine Information |
- Vaccine Name: Autologous Neuroblastoma Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Live, attenuated vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: interleukin-2 (IL-2) (NCT00048386)
- Immunization Route: subcutaneous injection
- Description: This vaccine uses autologous neuroblastoma cells, irradiated and genetically modified by adenoviral vectors to secrete interleukin-2 (IL-2) for patients with high-risk neuroblastoma. The adenoviral vector are used to transduce the cells ex-vivo, patients are not treated with the viral vector. (NCT00048386)
|
| Host Response |
|
|
| References |
NCT00048386: Neuroblastoma Vaccine for Treatment of High-Risk Neuroblastoma After Chemotherapy (CYCHE2) [https://clinicaltrials.gov/study/NCT00048386]
|
|
